GlaxoWellcome

GlaxoWellcome
Ian Wilson · CC BY 2.0 · source
Name	GlaxoWellcome
Fate	Merged
Successor	GlaxoSmithKline
Founded	0 1995
Defunct	0 2000
Key people	Sir Richard Sykes
Industry	Pharmaceutical industry
Products	Prescription medicines, Vaccines
Location	London, United Kingdom

GlaxoWellcome was a major British pharmaceutical company formed by the merger of Glaxo and Wellcome in 1995. It rapidly became one of the world's largest pharmaceutical firms, known for its blockbuster anti-viral and respiratory medicines. The company operated globally with significant research facilities in the United Kingdom and the United States before its merger with SmithKline Beecham in 2000 to form GlaxoSmithKline.

History

The origins of GlaxoWellcome trace back to its two constituent companies, each with long histories. Glaxo began in the 19th century as a New Zealand-based food company before shifting to pharmaceuticals, famously developing baby food and later key antibiotics. Its rival, Wellcome, was founded in London by American pharmacists Silas Burroughs and Henry Wellcome, establishing a legacy in research that led to the creation of the Wellcome Trust, one of the world's largest biomedical charities. Prior to their merger, both companies were significant players during the post-war expansion of the pharmaceutical industry, with Glaxo achieving great success with its anti-ulcer drug Zantac.

Formation and operations

The merger between Glaxo and Wellcome was finalized in 1995, creating a pharmaceutical giant with combined annual sales exceeding £7 billion. The integration was overseen by Chairman Sir Richard Sykes, a former research director at Glaxo, who aimed to consolidate research efforts and streamline operations. Major research and development hubs were maintained at sites like Stevenage and the former Wellcome Research Laboratories in Beckenham. The company's global headquarters were in London, with substantial commercial operations in the Research Triangle Park area of North Carolina, strengthening its presence in the critical American market.

Major products

GlaxoWellcome's portfolio was dominated by several world-leading medicines. The anti-viral drug Zovirax (aciclovir), originally a Wellcome product for treating herpes simplex, remained a significant revenue generator. The company's respiratory franchise was anchored by Ventolin (salbutamol) and the newer Serevent (salmeterol), important treatments for asthma and chronic obstructive pulmonary disease. It also marketed Zinacef (cefuroxime), a broad-spectrum antibiotic, and had a growing pipeline in HIV therapy, including Retrovir (zidovudine). Research efforts continued in areas like oncology and vaccines.

Merger into GlaxoSmithKline

In January 2000, GlaxoWellcome announced a planned merger with another British-American rival, SmithKline Beecham, itself the product of a prior merger between SmithKline Beckman and Beecham Group. The deal, valued at nearly £114 billion, was driven by pressures of research and development costs, patent expirations on key drugs like Zantac, and the need for greater scale in a consolidating global industry. After regulatory approvals from bodies like the Federal Trade Commission and the European Commission, the merger was completed in December 2000, forming GlaxoSmithKline (GSK), which immediately became one of the largest pharmaceutical companies globally.

Legacy and impact

The legacy of GlaxoWellcome is deeply embedded in the structure of the modern pharmaceutical landscape. Its merger to create GlaxoSmithKline set a precedent for industry consolidation, influencing subsequent mega-mergers like Pfizer's acquisition of Warner-Lambert. The company's focus on high-volume blockbuster drugs shaped R&D strategies across the sector. Furthermore, the enduring influence of the Wellcome Trust, which sold its stake in the merged entity, continues to fund vast amounts of global biomedical research. Many of its former research sites remain critical centers for GlaxoSmithKline, and its products continue to be mainstays of treatment worldwide.

Category:Pharmaceutical companies of the United Kingdom Category:Companies established in 1995 Category:Companies disestablished in 2000